AZN will by future earnings (like the competition). I believe they are doing their due diligence even as we write. In the long run it is far more cost efficient to pay a fair price for a stock that has done all the hard work and by pass all the costs of the failures. There are some very interesting companies that have some game changing treatments for ALS, stroke, depression etc. Neuralstem (cur) is just one such company. Once the trials confirm the early indicators AZN will likely look to partner or buy out completely. The earlier they buy the cheaper they can get the stock. I own some of both stocks and I see a great marriage here. AZN has the power to market CUR's exciting small molecules. AZN would be a strong competitor to SNY with the CUR ALS approach. It looks like the CUR ALS will actually halt the progress of this fatel disease. The AZN network would probably be able to get this in the hands of patiente faster and perhaps more cost effectively. The DOD and the NFL are interested in CURs therapies for head trauma and PTS patients. CUR could be a real good fit for AZN. I also own a little MRK but I don't see the same fit there.